GlyCardial Diagnostics’ technology is based on the quantification of specific protein modifications as a novel and disruptive approach to detect cardiac ischemia

– Technology –

 Novel and proprietary method

Based on specific monoclonal antibodies, for the specific detection of target glycosylated forms of Apo J

– Clinical benefits –

Diagnostic and Prognostic Value

Early detection (15-30 minutes from ischemia onset). 

Ischemic risk stratification.

– Diagnostic tool benefits –

Monoclonal antibody technology

Allows standardisation and upscaling

Marker with comparably high concentration

Applicable to standard immunochemistry and point-of-care detection technologies